WuXi PharmaTech Well Positioned to Continue Growin

43c47jgn31jh

WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that its previously announced transaction with Charles River Laboratories International Inc. (NYSE: CRL) has been terminated by mutual agreement due to Charles River shareholder opposition. Under the terms of the termination agreement, WuXi will receive a breakup fee of $30 million.

"WuXi‘s strategy has not changed. Our goal is, and has long been, to build a broad,[link widoczny dla zalogowanych], integrated R&D service platform designed to help our customers improve the success of research and shorten the time of new product development,[link widoczny dla zalogowanych]," said Dr. Ge Li, Chairman and Chief Executive Officer. "While we are disappointed that this transaction could not be completed,[link widoczny dla zalogowanych], WuXi remains well positioned to meet our customers‘ needs and to continue to grow and expand as a standalone company.

"All of our businesses are performing very well," Dr. Li continued. "Each business unit has met or exceeded its targets for the second quarter, and we recently increased our guidance for full-year 2010 financial performance.

"Virtually all of the large global pharmaceutical companies, as well as hundreds of smaller pharmaceutical and biotech companies and many leading medical device companies,[link widoczny dla zalogowanych], are our customers," Dr. Li concluded. "We believe that strong trends for greater outsourcing and offshoring of R&D services will continue, and that WuXi, as the leading China-based contract research organization, is well positioned to benefit from this powerful outsourcing trend for many years to come."

Second Quarter Results

WuXi will report financial results for the second quarter ending June 30,[link widoczny dla zalogowanych], 2010, on Monday, August 2, at 6:30 am EDT with a conference call at 8:30 am EDT to discuss the results and the outlook for WuXi‘s business. The conference call may be accessed by calling:

United States: 1-866-519-4004
China (Landline): 800-819-0121
China (Mobile): 400-620-8038
Hong Kong: 800-930-346
United Kingdom: 0-808-234-6646
International: +65-6723-9381
Conference ID: 90840146
Web PIN: 8656

A replay will be available two hours after the call‘s completion at:

United States: 1-866-214-5335
China North: 10-800-714-0386
China South: 10-800-140-0386
Hong Kong: 800-901-596
United Kingdom: 0-800-731-7846
International: +61-2-8235-5000
Passcode: 90840146

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech‘s website at .